

10/529284

JC17 Rec'd PCT/PTO 25 MAR 2005

**In the Claims:**

Please amend the claims as follows:

1. (Currently Amended) A solid dosage form for oral administration comprising a coherent matrix with a disintegration time of less than 2 minutes, wherein:

[[~~-~~]]the matrix comprises an active ingredient which is slightly soluble in a physiological fluid and which is in the form of fast-release capsules selected from at least one of micro- ~~or~~ and nanocapsules,

[[~~-~~]]the ~~micro-or nanocapsules~~ capsules comprise a core and a shell,

[[~~-~~]]the core comprises the slightly soluble active ingredient,

[[~~-~~]]the shell consists essentially of a material with high permeability for the slightly soluble active ingredient, and

[[~~-~~]]the shell of the ~~micro-or nanocapsules~~ capsules comprises a complex of at least one polyelectrolyte and a counter ion to the polyelectrolyte.

2. (Original) The dosage form as claimed in claim 1, characterized in that the matrix has a disintegration time of less than 30 seconds.

3. (Currently Amended) The dosage form as claimed in claim 1~~or~~2, characterized in that release of ~~its~~ the active ingredient is virtually complete within 30 minutes.

4. (Currently Amended) The dosage form as claimed in ~~any of the preceding claims~~ claim 1, characterized in that it the matrix further comprises gelatin and mannitol in a ratio of 1:1 to 1:3.

5. (Currently Amended) The dosage form as claimed in ~~any of the preceding claims~~ claim 1, characterized in that the slightly soluble active ingredient is selected from at least one of an analgesic, a migraine remedy, a spasmolytic, an antiemetic, an antiallergic, an antidiarrheal, an antihypertensive, an antihypotensive, an antivertigo agent, a psychoactive drug, an antidote, habit cessation aid, an antiarrhythmic, a sedative, a hypnotic, a tocolytic, a diagnostic ~~or~~ and a substance to counter erectile

dysfunction.

6. (Currently Amended) The dosage form as claimed in ~~any of the preceding~~ claims claim 1, characterized in that the ~~micro-or nanocapsules~~ capsules have an average particle size of not more than about 10  $\mu\text{m}$ .

7. (Currently Amended) The dosage form as claimed ~~any of the preceding claims~~ in claim 1, characterized in that the counter ion is a polyelectrolyte.

8. (Currently Amended) The dosage form as claimed in ~~any of the preceding~~ claims claim 1, characterized in that the ~~micro-or nanocapsules~~ capsules are produced by layered electrostatic self-assembly.

9. (Currently Amended) The dosage form as claimed in ~~any of the preceding~~ claims claim 1, characterized in that the shell of the ~~micro-or nanocapsules~~ capsules comprises a material selected from at least one of a lipid layer ~~or and a~~ lipid bilayer.

10. (Currently Amended) The dosage form as claimed in ~~any of the preceding~~ claims claim 1, characterized in that the matrix is produced by compressing a material selected from at least one of powder ~~or and~~ granules.

11. (Currently Amended) The dosage form as claimed in ~~any of claims 1 to 9~~ claim 1, characterized in that the matrix is produced by freeze-drying a substance selected from at least one of a fluid ~~or and a~~ highly viscous composition.

12. (Currently Amended) The dosage form as claimed in ~~any of claims 1 to 9~~ claim 1, characterized in that the matrix is produced by ~~drying or~~ solidifying a composition which has been ~~extruded or spread out like~~ into a film.

13-16. (Canceled)

17. (New) The dosage form as claimed in claim 4, wherein the capsules have an average size of less than about 10  $\mu\text{m}$ .

18. (New) A method of producing a solid dosage form for oral administration that comprises a coherent matrix with a disintegration time of less than two minutes, comprising:

providing an active ingredient which is slightly soluble in a physiological fluid and which is in the form of fast-release capsules selected from at least one of micro- and nanocapsules, wherein the capsules comprise a core comprising the slightly soluble active ingredient and a shell consisting essentially of a material with high permeability for the slightly soluble active ingredient, the shell of the capsules comprising a complex of at least one polyelectrolyte and a counter ion to the polyelectrolyte;

mixing the capsules with matrix-forming, physiologically acceptable excipients to provide a mixture; and

forming the mixture into dose units.

19. (New) The method of claim 18, wherein forming the mixture into dose units includes compressing the mixture into tablets.

20. (New) The method of claim 18, further comprising mixing the mixture with a liquid carrier to provide a solution, wherein forming the mixture into dose units includes dividing and freeze-drying the solution.

21. (New) The method of claim 18, further comprising mixing the mixture with a liquid carrier to provide a solution, wherein forming the mixture into dose units includes spreading the solution into a film and drying the film.

22. (New) The method of claim 18, wherein the capsules have an average particle size less than about 10  $\mu\text{m}$ .

23. (New) The method of claim 18, wherein the active ingredient is a therapeutic.

24. (New) A method of producing a medicament for the treatment of acute diseases, comprising:

forming a coherent matrix with a disintegration time of less than two minutes, wherein the matrix comprises an active ingredient which is slightly soluble in a physiological fluid and which is in the form of fast-release capsules having an average size of less than about 10  $\mu\text{m}$ , wherein the capsules comprise a core comprising the active ingredient and a shell consisting essentially of a material with high permeability for the active ingredient, the shell of the capsules comprising a complex of at least one polyelectrolyte and a counter ion to the polyelectrolyte.